BHC Stock Recent News

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rumors circulated on a pre-packaged bankruptcy filing, which Bausch Health Companies quickly refuted. Bausch Health stock previously plummeted after posting Q1 results. BHC's cash flow remains weak, with concerns over long-term debt and limited resources for growth.

It was quite a day for shares of Bausch Health Cos. (BHC), which were cut nearly in half before recovering as it addressed a research firm's report saying it was mulling bankruptcy options.

Specialty pharmaceutical and medical device firm Bausch Health (NYSE: BHC ) saw its shares tumble badly on Wednesday. Driving the negativity was a report by Reorg — billed as a global provider of credit intelligence, data and analytics for leveraged finance professionals — that the company was on the brink of bankruptcy.

Bausch Health said on Wednesday it was not considering a bankruptcy or insolvency proceeding of any kind.

LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources. The article contains unsubstantiated rumors, including that the Company is considering a bankruptcy or insolvency proceeding of any kind - it is not.

Shares of Bausch Health Companies Inc. BHC, -21.60% have been halted for news, with the last trade at a 14-month low. The Canada-based drug and medical devices company's stock was down 21.6% when it was halted at 12:21 p.m.

LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT). Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024.

LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m.

LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced that it has filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Norwich Pharmaceuticals, Inc. This lawsuit was filed in connection with the Notice of Paragraph IV Certification, dated May 10, 2024, received from Norwich advising that it has submitted to the U.S. Food and Drug Administration (FDA) an amendment to an Abbreviated New Drug Application (ANDA) requesting approval to market a generic version of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Bausch Health continues to defend challenges to its XIFAXAN® intellectual property.